{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repaglinide", "query": { "intervention": "Repaglinide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repaglinide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T00:23:32.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05981365", "title": "Voxelotor CYP and Transporter Cocktail Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Flurbiprofen", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2023-04-17", "completion_date": "2023-10-04", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05981365" }, { "nct_id": "NCT07372625", "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TP53 Y220C Mutation", "Advanced Solid Tumors" ], "interventions": [ { "name": "metformin hydrochloride 500 mg tablet", "type": "DRUG" }, { "name": "rosuvastatin 10 mg tablet", "type": "DRUG" }, { "name": "repaglinide 0.5 mg tablet", "type": "DRUG" }, { "name": "midazolam hydrochloride syrup", "type": "DRUG" }, { "name": "rezatapopt", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07372625" }, { "nct_id": "NCT05602675", "title": "A Drug Interaction Study of LY3871801 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3871801", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2022-11-02", "completion_date": "2023-03-29", "has_results": false, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602675" }, { "nct_id": "NCT01489644", "title": "Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "repaglinide", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "repaglinide and metformin combination tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 62, "start_date": "2006-06", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 2, "location_summary": "Miami, Florida • Tacoma, Washington", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489644" }, { "nct_id": "NCT05444556", "title": "A Study of Imlunestrant (LY3484356) in Female Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 113, "start_date": "2022-07-07", "completion_date": "2022-11-02", "has_results": true, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 3, "location_summary": "Cypress, California • South Miami, Florida • San Antonio, Texas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05444556" }, { "nct_id": "NCT00072904", "title": "Diabetes Therapy to Improve BMI and Lung Function in CF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis", "Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Asparte", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 108, "start_date": "2001-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-02-28", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 6, "location_summary": "Palo Alto, California • Springfield, Massachusetts • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072904" }, { "nct_id": "NCT00763412", "title": "Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis Related Diabetes", "Pancreatic Insufficiency" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbelaez, Ana Maria", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "12 Years to 24 Years" }, "enrollment_count": 31, "start_date": "2006-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00763412" }, { "nct_id": "NCT05469113", "title": "A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Repaglinide", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-01-29", "completion_date": "2019-03-05", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469113" }, { "nct_id": "NCT04008186", "title": "A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Subjects" ], "interventions": [ { "name": "Omaveloxolone", "type": "DRUG" }, { "name": "Midazolam oral solution", "type": "DRUG" }, { "name": "Repaglinide 1 MG", "type": "DRUG" }, { "name": "MetFORMIN 500 Mg Oral Tablet", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Digoxin tablet", "type": "DRUG" }, { "name": "Gemfibrozil Tablets", "type": "DRUG" }, { "name": "Itraconazole capsule", "type": "DRUG" }, { "name": "Verapamil Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 61, "start_date": "2019-06-14", "completion_date": "2019-08-28", "has_results": false, "last_update_posted_date": "2025-05-30", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008186" }, { "nct_id": "NCT06092931", "title": "A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "DC-806", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2023-10-16", "completion_date": "2023-11-28", "has_results": false, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-09-02T00:23:32.891Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06092931" } ] }